In men with prostate cancer after prostatectomy, goserelin plus radiotherapy increased progression-free survival versus radiotherapy alone: 64% versus 49%, hazard ratio 0·54.
In plain wordsIn men with prostate cancer after surgery, adding goserelin increased progression-free survival compared with radiotherapy alone.
- Peptide
- Goserelin
- Outcome
- IncreaseProgression-free survival at 120 months
- Study
n = 743
- Comparator
- Radiotherapy alone
- Analysis
- Primary
- Outcome group
- Tumor growth · Cancer
- Studied dose
- 10·8 mg on the first day of irradiation and 3 months later · subcutaneousAs given in this study (human).
Measurements
- Progression-free survival
- 64%
- goserelin plus radiotherapy
- Progression-free survival
- 49%
- radiotherapy alone
- Hazard ratio
- 0.54
- 95% CI 0·43-0·68; p<0·0001
Source sentences
The 120-month progression-free survival was 64% (95% CI 58-69) for patients treated with radiotherapy plus goserelin and 49% (43-54) for patients treated with radiotherapy alone (hazard ratio 0·54, 0·43-0·68; stratified log-rank test p<0·0001).
1 context sentence(design, population, supporting numbers)
Patients were assigned through central randomisation (1:1) to short-term androgen suppression (subcutaneous injection of 10·8 mg goserelin on the first day of irradiation and 3 months later) plus radiotherapy (3D conformal radiotherapy or intensity modulated radiotherapy of 66 Gy in 33 fractions, 5…